Page last updated: 2024-11-03

propranolol and Pain, Chronic

propranolol has been researched along with Pain, Chronic in 2 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

ExcerptRelevanceReference
"Propranolol's efficacy in reducing facial pain index was greater among the 104 migraineurs than the 95 non-migraineurs: For example, for the binary ≥ 30% reduction in facial pain index, odds ratios were 3."5.41Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. ( Arbes, SJ; Campbell, JH; Fillingim, RB; Giosia, MD; Hadgraft, H; Lim, PF; Ohrbach, R; Ribeiro-Dasilva, M; Slade, GD; Tchivileva, IE; Willis, J, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Tchivileva, IE1
Ohrbach, R1
Fillingim, RB2
Lim, PF1
Giosia, MD1
Ribeiro-Dasilva, M1
Campbell, JH1
Hadgraft, H1
Willis, J1
Arbes, SJ1
Slade, GD1
George, SZ1
Staud, R1
Borsa, PA1
Wu, SS1
Wallace, MR1
Greenfield, WH1
Mackie, LN1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383]Phase 2200 participants (Actual)Interventional2015-08-20Completed
Biopsychosocial Influence on Shoulder Pain: a Randomized, Pre-clinical Trial[NCT02620579]Phase 2264 participants (Actual)Interventional2016-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Diastolic Blood Pressure After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm Hg (Least Squares Mean)
Propranolol ER-3.3
Placebo1.0

Change in Heart Rate After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionbeats per minute (Least Squares Mean)
Propranolol ER-3.9
Placebo1.5

Change in Maximum Assisted Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER-0.3
Placebo-0.8

Change in Maximum Unassisted Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER-0.9
Placebo-1.2

Change in Pain-free Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER4.5
Placebo1.4

Change in Pressure Pain Threshold at Lateral Epicondyle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER41.4
Placebo22.7

Change in Pressure Pain Threshold at Masseter Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)

InterventionkPa (Least Squares Mean)
Propranolol ER38.3
Placebo29.3

Change in Pressure Pain Threshold at Temporalis Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER41.8
Placebo38.4

Change in Pressure Pain Threshold at Temporomandibular Joint After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER36.8
Placebo25.3

Change in Pressure Pain Threshold at Trapezius Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER64.1
Placebo63.3

Change in Systolic Blood Pressure After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm Hg (Least Squares Mean)
Propranolol ER-3.6
Placebo1.3

Change in the Headache Impact Test (HIT-6) Global Score After 9 Weeks of Treatment

"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-5.1
Placebo-3.1

Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Score After 9 Weeks of Treatment

"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.3
Placebo-0.7

Change in the Hospital Anxiety and Depression Scale (HADS) Depression Score After 9 Weeks of Treatment

"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.0
Placebo-0.6

Change in the Jaw Functional Limitation Scale (JFLS) Global Score After 9 Weeks of Treatment

"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.1
Placebo-0.8

Change in the Perceived Stress Scale (PSS) Global Score After 9 Weeks of Treatment

"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-2.6
Placebo-1.9

Change in the Pittsburgh Sleep Quality Index (PSQI) Global Score After 9 Weeks of Treatment

The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-0.7
Placebo-1.0

Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) After 9 Weeks of Treatment

"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER3.6
Placebo2.8

Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) After 9 Weeks of Treatment

"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER1.2
Placebo0.3

Change in the SF-McGill Pain Questionnaire Affective Component After 9 Weeks of Treatment

"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-2.9
Placebo-3.1

Change in the SF-McGill Pain Questionnaire Present Facial Pain Intensity After 9 Weeks of Treatment

"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-0.9
Placebo-0.7

Change in the SF-McGill Pain Questionnaire Sensory Component After 9 Weeks of Treatment

"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.9
Placebo-1.6

Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Duration After 9 Weeks of Treatment

"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-23.6
Placebo-21.6

Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Intensity After 9 Weeks of Treatment

"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-18.2
Placebo-15.8

Change in the SF-McGill Pain Questionnaire Weekly Fatigue After 9 Weeks of Treatment

"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-12.0
Placebo-11.4

Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale Score After 9 Weeks of Treatment

"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-0.2
Placebo-0.2

Change in the Weekly Mean Pain Duration After 9 Weeks of Treatment

"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-17.9
Placebo-16.6

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-13.9
Placebo-12.1

Change in the Weekly Mean Pain Intensity After 9 Weeks of Treatment

"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-17.1
Placebo-13.6

Change in Thermal Pain Threshold After 9 Weeks of Treatment

Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventiondegrees Celsius (Least Squares Mean)
Propranolol ER1.3
Placebo0.5

Change in Thermal Pain Tolerance After 9 Weeks of Treatment

Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventiondegrees Celsius (Least Squares Mean)
Propranolol ER0.5
Placebo0.4

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT LPS Haplotypes

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

,
Interventionunits on a scale (Least Squares Mean)
0 LPS haplotypes1 LPS haplotype2 LPS haplotypes
Placebo-12.3-13.2-2.5
Propranolol ER-14.2-12.2-15.2

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT Valine Alleles at rs4680

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

,
Interventionunits on a scale (Least Squares Mean)
0 valine alleles1 valine allele2 valine alleles
Placebo-13.9-13.1-9.7
Propranolol ER-14.2-13.9-14.3

Brief Pain Inventory (BPI) for Pain Duration

The Brief Pain Inventory (BPI) consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). BPI will be recorded daily and the recovery criterion used for this study will be a BPI rating of current pain 0/10 and worst pain rating of less than 2/10. The pain duration is number of days from the date of induced pain to date of recovery. The longer the duration means a worse outcome. (NCT02620579)
Timeframe: Daily until recovery criterion met, approximately 5-15 days

Interventiondays (Median)
Personalized Pharmaceutical and Education (C)4
Placebo Pharmaceutical, General Education (B)4
Placebo Pharmaceutical, Personalized Education (A)4
Personalized Pharmaceutical, General Education (D)4

Brief Pain Inventory (BPI) for Worst Shoulder Pain Intensity (Highest Daily Pain Intensity Rating) Recorded During Recovery.

The Brief Pain Inventory (BPI) which consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). Participants will rate their current, best, and worst pain intensity on the BPI. This measure will be recorded daily through study completion, an average of 5 days. The worst pain intensity rating at Day 2 (when participants usually had the Peak Shoulder Pain Intensity) is reported. (NCT02620579)
Timeframe: Day 2 value of the worst pain intensity is reported

Interventionscore on a scale (Mean)
Personalized Pharmaceutical and Education (C)2.9
Placebo Pharmaceutical, General Education (B)3.2
Placebo Pharmaceutical, Personalized Education (A)2.9
Personalized Pharmaceutical, General Education (D)3.1

Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH)

The abridged version of the DASH (the QuickDASH) which consists of 11 functional items, with total scores ranging from 0 (not disability) to 100 (complete disability) will be used to assess upper-extremity disability. The primary outcome will be the highest DASH score recorded during the pain intensity recovery period. (NCT02620579)
Timeframe: Daily until recovery criterion met, approximately 5-15 days

Interventionscore on a scale (Mean)
Personalized Pharmaceutical and Education (C)8.2
Placebo Pharmaceutical, General Education (B)10.5
Placebo Pharmaceutical, Personalized Education (A)11.4
Personalized Pharmaceutical, General Education (D)9.4

Number of Participants Who Met the Recovery Criterion for Shoulder Pain Intensity

The outcome has a range between 0 and 1, the higher scores mean a better outcome. Successful recovery was determined based on meeting the recovery criterion for shoulder pain intensity by at least 6 days. Specifically, recovery (Yes or No) was defined using Brief Pain Inventory (BPI) ratings as a current pain intensity rating of 0/10 and a worst pain intensity rating of less than 2/10. (NCT02620579)
Timeframe: Approximately 6 days

InterventionParticipants (Count of Participants)
Personalized Pharmaceutical and Education (C)39
Placebo Pharmaceutical, General Education (B)32
Placebo Pharmaceutical, Personalized Education (A)32
Personalized Pharmaceutical, General Education (D)32

Trials

2 trials available for propranolol and Pain, Chronic

ArticleYear
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
    Cephalalgia : an international journal of headache, 2021, Volume: 41, Issue:7

    Topics: Adolescent; Adult; Aged; Autonomic Nervous System; Chronic Pain; Double-Blind Method; Facial Pain; F

2021
Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.
    Contemporary clinical trials, 2017, Volume: 56

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Catastrophization; Catechol O-Methyltransferas

2017